CTOs on the Move

Omnicare Distribution Center

www.omnicaredc.com

 
Omnicare Distribution Center is a Toledo, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $100-250 Million

Executives

Name Title Contact Details

Similar Companies

Seattle Institute for Biomedical and Clinical Research

Seattle Institute for Biomedical and Clinical Research is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Biotech Medical

Biotech Medical is a Canton, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Mirixa

We are advocates, not just providers. Leading health plans and patients to better outcomes through a broad range of medication therapy management (MTM) programs. Empowering connections that matter. Mirixa is the leading provider of MTM and targeted, pharmacist-delivered services to health plans. An MTM pioneer, we`ve been building connections since 2006 - harnessing the knowledge and skills of pharmacists to engage more patients and deliver measureable results. We have the largest and most comprehensive pharmacy services network in North America. And we create leading edge programs that reach beyond Medicare Part D compliance, helping health plans of all types deliver a more focused patient experience and positive outcome, while potentially reducing total healthcare costs. Our goal is your goal: to ultimately empower every patient to live a fuller, healthier life.

Soliance

Soliance is a Allendale, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

DynamiCure

DynamiCure is employing a platform-agnostic approach to discover and develop therapeutics designed to address significant unmet medical needs in oncology and autoimmune disease. We are driven by science and passionate about advancing patient care, translating pioneering new insights on immuno-normalization into a pipeline of innovative candidates with first-in-class and best-in-class potential. Since our founding in 2019, we have identified and obtained exclusive global rights to several novel targets and are rapidly advancing into the clinic both monoclonal and bispecific therapeutic antibody candidates.